Bioequivalence study of MTD201 (Q-Octreotide)

Trial Profile

Bioequivalence study of MTD201 (Q-Octreotide)

Planning
Phase of Trial: Phase I

Latest Information Update: 09 Jan 2018

At a glance

  • Drugs Octreotide (Primary)
  • Indications Acromegaly; Malignant carcinoid syndrome
  • Focus First in man; Pharmacokinetics; Registrational
  • Sponsors Midatech
  • Most Recent Events

    • 09 Jan 2018 According to a Midatech media release, initial exploratory phase is expected to complete by mid-2018, and the final confirmatory phase is expected to complete in H2 2018.
    • 09 Jan 2018 According to a Midatech media release, this study has received oral confirmation from Polish regulators and Formal written confirmation of the approval is expected within the next two weeks.
    • 02 Sep 2016 According to a Midatech Pharma media release, the company plans to initiate bio-equivalence study in first half of 2017 which, in the case of positive results, could lead to the potential filing for first marketing authorisations by end 2017 or beginning of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top